Miocardiopatías. Miocardiopatía hipertrófica

  1. García Campos, A. 1
  2. Pérez Domínguez, M. 1
  3. Díaz Fernández, B. 1
  4. González Juanetey, J.R. 1
  1. 1 Servicio de Cardiología. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. La Coruña. España. CIBERCV
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (VIII)

Serie: 13

Número: 42

Páginas: 2433-2446

Tipo: Artículo

DOI: 10.1016/J.MED.2021.09.020 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Cardiomyopathies are a heterogeneous group of pathologies which have in common involvement of the ventricular myocardium in absence of overload or coronary, valve, or congenital disease that justifies it. They can be classified according to their phenotype. Hypertrophic cardiomyopathy is defined by an increase in left ventricle parietal thickness and is frequently associated with outflow tract obstruction and systolic anterior motion of the mitral valve. Sudden death can be one of the symptoms of this disease and risk stratification is of vital importance for deciding on the need for implantation of an automated defibrillator, whose use has been the main cause of a reduction in mortality in these patients in recent decades.

Referencias bibliográficas

  • P. Elliott, B. Andersson, E. Arbustini, Z. Bilinska, F. Cecchi, P. Charron Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases Eur Heart J., 29 (2) (2007), pp. 270-276
  • B.J. Maron, J.A. Towbin, G. Thiene, C. Antzelevitch, D. Corrado, D. Arnett Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology Heart Failure and Transplantation Committee; Quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation., 113 (14) (2006), pp. 1807-1816
  • F.I. Marcus, W.J. McKenna, D. Sherrill, C. Basso, B. Bauce, D.A. Bluemke Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria Eur Heart J., 31 (7) (2010), pp. 806-814
  • D. Corrado, C. Basso, D.P. Judge Arrhythmogenic cardiomyopathy Circ Res., 121 (7) (2017), pp. 784-802
  • E. Arbustini, N. Narula, L. Tavazzi, A. Serio, M. Grasso, V. Favalli The MOGE(S) Classification of Cardiomyopathy for Clinicians J Am Coll Cardiol., 64 (3) (2014), pp. 304-318
  • C. Semsarian, J. Ingles, M.S. Maron, B.J. Maron New perspectives on the prevalence of hypertrophic cardiomyopathy J Am Coll Cardiol., 65 (12) (2015), pp. 1249-1254
  • B.J. Maron, E.J. Rowin, M.S. Maron global burden of hypertrophic cardiomyopathy JACC Heart Fail., 6 (5) (2018), pp. 376-378
  • N.K. Lakdawala, I. Olivotto, S.M. Day, L. Han, E.A. Ashley, M. Michels Associations between female sex, sarcomere variants and clinical outcomes in hypertrophic cardiomyopathy Circ Genom Precis Med., 14 (1) (2021), p. e003062
  • A.A. Geisterfer Lowrance, S. Kass, G. Tanigawa, H.P. Vosberg, W. McKenna, C.E. Seidman A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation Cell., 62 (5) (1990), pp. 999-1006
  • M.A. Burke, S.A. Cook, J.G. Seidman, C.E. Seidman Clinical and mechanistic insights into the genetics of cardiomyopathy J Am Coll Cardiol., 68 (25) (2016), pp. 2871-2886
  • C.E. Seidman, J.G. Seidman Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history. J. Robbins, H. Watkins (Eds.), Circ Res. 108(6) (2011), pp. 743-750
  • P. Richard, P. Charron, L. Carrier, C. Ledeuil, T. Cheav, C. Pichereau Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy Circulation., 107 (17) (2003), pp. 2227-2232
  • A.J. Marian, E. Braunwald Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy Circ Res., 121 (7) (2017), pp. 749-770
  • J. Ingles, J. Goldstein, C. Thaxton, C. Caleshu, E.W. Corty, S.B. Crowley Evaluating the clinical validity of hypertrophic cardiomyopathy genes Circ Genom Precis Med. Feb, 12 (2) (2019), p. e002460
  • B.J. Maron, S.R. Ommen, C. Semsarian, P. Spirito, I. Olivotto, M.S. Maron Hypertrophic cardiomyopathy J Am Coll Cardiol., 64 (1) (2014), pp. 83-99
  • H. Niimura, L.L. Bachinski, S. Sangwatanaroj, H. Watkins, A.E. Chudley, W. McKenna Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy N Engl J Med., 338 (18) (1998), pp. 1248-1257
  • N.M. Popa Fotea, M.M. Micheu, V. Bataila, A. Scafa Udriste, L. Dorobantu, A.I. Scarlatescu Exploring the continuum of hypertrophic cardiomyopathy—from DNA to clinical expression Medicina (Mex)., 55 (6) (2019), p. 299
  • A.M. Varnava, P.M. Elliott, S. Sharma, W.J. McKenna, M.J. Davies Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease Heart Br Card Soc., 84 (5) (2000), pp. 476-482
  • J.Shirani, R. Pick, W.C. Roberts, B.J. Maron Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death J Am Coll Cardiol., 35 (1) (2000), pp. 36-44
  • M.S. Maron, I. Olivotto, A.G. Zenovich, M.S. Link, N.G. Pandian, J.T. Kuvin Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction Circulation, 114 (21) (2006), pp. 2232-2239
  • M.S. Maron, I. Olivotto, C. Harrigan, E. Appelbaum, C.M. Gibson, J.R. Lesser Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy Circulation., 124 (1) (2011), pp. 40-47
  • S.R. Ommen, S. Mital, M.A. Burke, S.M. Day, A. Deswal, P. Elliott AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation., 142 (25) (2020), pp. e533-e557
  • M.S. Maron, I. Olivotto, S. Betocchi, S.A. Casey, J.R. Lesser, M.A. Losi Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy N Engl J Med., 348 (4) (2003), pp. 295-303
  • B.J. Maron Clinical course and management of hypertrophic cardiomyopathy D.L. Longo (Ed.), N Engl J Med. 379(7) (2018), pp. 655-668
  • P. Nihoyannopoulos, G. Karatasakis, M. Frenneaux, W.J. McKenna, C.M. Oakley Diastolic function in hypertrophic cardiomyopathy: Relation to exercise capacity J Am Coll Cardiol., 19 (3) (1992), pp. 536-540
  • I. Olivotto, F. Cecchi, C. Poggesi, M.H. Yacoub Patterns of disease progression in hypertrophic cardiomyopathy: An individualized approach to clinical staging Circ Heart Fail., 5 (4) (2012), pp. 535-546
  • I. Olivotto, B.J. Maron, E. Appelbaum, C.J. Harrigan, C. Salton, C.M. Gibson Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy Am J Cardiol., 106 (2) (2010), pp. 261-267
  • L. Monserrat, P.M. Elliott, J.R. Gimeno, S. Sharma, M. Penas-Lado, W.J. McKenna Non sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients ACC Curr J Rev., 13 (1) (2004), pp. 54-55
  • O.P. Guttmann, M.S. Rahman, C. O’Mahony, A. Anastasakis, P.M. Elliott Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review Heart., 100 (6) (2014), pp. 465-472
  • C.E. Raphael, R. Cooper, K.H. Parker, J. Collinson, V. Vassiliou, D.J. Pennell Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy J Am Coll Cardiol., 68 (15) (2016), pp. 1651-1660
  • J.B. Geske, S.R. Ommen, B.J. Gersh Hypertrophic cardiomyopathy: clinical update JACC Heart Fail., 6 (5) (2018), pp. 364-375
  • P.M. Elliott, J.C. Kaski, K. Prasad, H. Seo, A.K. Slade, J.H. Goldman Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study Eur Heart J., 17 (7) (1996), pp. 1056-1064
  • S.S. Zhai, C.M. Fan, S.Y. An, F. Hang, Y.J. Yang, L.R. Yan Clinical outcomes of myocardial bridging versus no myocardial bridging in patients with apical hypertrophic cardiomyopathy Cardiology., 139 (3) (2018), pp. 161-168
  • L. Williams, M. Frenneaux Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment Europace., 9 (9) (2007), pp. 817-822
  • B.J. Maron, S.A. Casey, T.S. Haas, C.L. Kitner, R.F. Garberich, J.R. Lesser Hypertrophic cardiomyopathy with longevity to 90 years or older Am J Cardiol., 109 (9) (2012), pp. 1341-1347
  • C. Autore, M.B. Musumeci The natural history of hypertrophic cardiomyopathy Eur Heart J Suppl., 22 (Supl) (2010), pp. L11-L14
  • B.J. Maron, E.J. Rowin, S.A. Casey, T.S. Haas, R.H.M. Chan, J.E. Udelson Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥ 60 years of age Circulation., 127 (5) (2013), pp. 585-593
  • J. Bogaert, I. Olivotto MR Imaging in hypertrophic cardiomyopathy: From magnet to bedside Radiology., 273 (2) (2014), pp. 329-348
  • M.S. Maron, B.J. Maron Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy Circulation., 132 (4) (2015), pp. 292-298
  • R.E. Hershberger, M.M. Givertz, C.Y. Ho, D.P. Judge, P.F. Kantor, K.L. McBride Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline J Card Fail., 24 (5) (2018), pp. 281-302
  • P.M. Elliott, J.R. Gimeno Blanes, N.G. Mahon, J.D. Poloniecki, W.J. McKenna Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy The Lancet., 357 (9254) (2001), pp. 420-424
  • M.S. Maron, J.J. Finley, J.M. Bos, T.H. Hauser, W.J. Manning, T.S. Haas Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy Circulation., 118 (15) (2008), pp. 1541-1549
  • R.H. Chan, B.J. Maron, I. Olivotto, M.J. Pencina, G.E. Assenza, T. Haas Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy Circulation., 130 (6) (2014), pp. 484-495
  • G.Todiere, C. Nugara, G. Gentile, F. Negri, F. Bianco, C. Falletta Prognostic role of late gadolinium enhancement in patients with hypertrophic cardiomyopathy and low-to-intermediate sudden cardiac death risk score Am J Cardiol., 124 (8) (2019), pp. 1286-1292
  • R.E. Stenson, M.D. Flamm, C. Harrison, E.W. Hancock Hypettrophic subaortic stenosis Am J Cardiol., 31 (1973), p. 11
  • R.O. Bonow, D.R. Rosing, S.L. Bacharach, M.V. Green, K.M. Kent, L.C. Lipson Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy Circulation., 64 (4) (1981), pp. 787-796
  • B.J. Maron, E.J. Rowin, J.E. Udelson, M.S. Maron Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy JACC Heart Fail., 6 (5) (2018), pp. 353-363
  • M.V. Sherrid, A. Shetty, G. Winson, B. Kim, D. Musat, C.L. Alviar treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil Circ Heart Fail., 6 (4) (2013), pp. 694-702
  • B.J. Maron, J.A. Dearani, S.R. Ommen, M.S. Maron, H.V. Schaff, R.A. Nishimura Low operative mortality achieved with surgical septal myectomy J Am Coll Cardiol., 66 (11) (2015), pp. 1307-1308
  • A. Batzner, B. Pfeiffer, A. Neugebauer, D. Aicha, C. Blank, H. Seggewiss Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy J Am Coll Cardiol., 72 (24) (2018), pp. 3087-3094
  • P. Ponikowski, A.A. Voors, S.D. Anker, H. Bueno, J.G.F. Cleland, A.J.S. Coats ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J., 37 (27) (2016), pp. 2129-2200
Fuente de los datos: Dialnet